Inetetamab in combination with rapamycin and chemotherapy for trastuzumab‐treated metastatic human epidermal growth factor receptor 2‐positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) overexpression is an independent prognostic factor of poor prognosis and a predictor of efficacy of anti‐HER2 therapy. A limited number of patients can receive standard second‐line therapy (DS‐8201 or T‐DM1) for metastatic HER2‐positive in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Aijuan, Li, Chenghui, Jiang, Qi'an, Jiang, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480495/
https://www.ncbi.nlm.nih.gov/pubmed/37501598
http://dx.doi.org/10.1002/cnr2.1864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480495/
https://www.ncbi.nlm.nih.gov/pubmed/37501598
http://dx.doi.org/10.1002/cnr2.1864

Ejemplares similares